Clinical trials: Non-hodgkins Lymphoma
Lymphoma, Non-Hodgkin
Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma
Almost two-thirds of lymphoma cases are Non-Hodgkin's Lymphomas (NHL). NHL is a malignant process that affects lymphoid cells found both in the lymph nodes and extranodally.
- Trial name
- NCT00044551
- Testing
- Taxane (Cytotoxic, BAY59-8862)
- Where
- 23 sites in United States, Canada and 4 more
- Volunteers
- 29 people
- Sponsor
- Bayer
Lymphoblastic Lymphoma
Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma
The main purpose of this study is to determine if it is feasible to administer an intensified, multi-agent chemotherapy regimen for children with stage III and IV non-Hodgkin lymphoma and to find out what the toxicities are.
- Trial name
- NCT00187122
- Testing
- Vincristine, Radiation Therapy, Daunomycin
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- St. Jude Children's Research Hospital
Chemotherapy-induced Febrile Neutropenia
Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
To estimate the incidence of febrile neutropenia in patients with breast cancer and non-Hodgkin's lymphoma receiving high (> 20%) FN-risk chemotherapy and pegfilgrastim primary prophylaxis.
- Trial name
- NCT02178475
- Where
- 74 sites in Austria, Belgium and 7 more
- Volunteers
- 943 people
- Sponsor
- Amgen
HIV Infections, Lymphoma, Non-Hodgkin
Therapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood Cell Transplantation Following Chemotherapy.
Given the poor prognosis of HIV-associated non-Hodgkin's lymphoma (NHL) and it's still high incidence in HAART era, more intensive therapy is required in patients with initially severe stage of NHL or relapsing after first-line…
- Trial name
- NCT00432419
- Testing
- autologous peripheral blood cell transplantation
- Where
- France
- Volunteers
- 1 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Mantle Cell Lymphoma
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to assess the safety, tolerability and activity of the combination of bendamustine and rituximab in patients with relapsed/refractory mantle cell lymphoma who are not eligible for high dose…
- Trial name
- NCT01170052
- Testing
- Temsirolimus, Bendamustine
- Where
- 3 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Charite University, Berlin, Germany
Non-Hodgkin's Lymphoma
A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)
This Phase II, single-arm, open-label, multicenter trial is designed to evaluate the safety, efficacy, and pharmacokinetics of PRO95780 when combined with rituximab in patients with follicular, CD20-positive B-cell NHL that has…
- Trial name
- NCT00517049
- Testing
- PRO95780, rituximab
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting CD7 in patients with relapsed or refractory CD7 positive T-cell hematological maliganacies
- Conditions
- T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT05290155
- Testing
- anti-CD7 CAR-T cells
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Follicular Lymphoma (FL), Non Hodgkin Lymphoma
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
This is a Phase 3 study of the PI3Kδ inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL…
- Conditions
- Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT04745832
- Testing
- Zandelisib, Rituximab, Bendamustine
- Where
- 141 sites in United States, Australia and 17 more
- Volunteers
- 82 people
- Sponsor
- MEI Pharma, Inc.
Breast Carcinoma, Colorectal Carcinoma
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed…
- Conditions
- Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma
- Trial name
- COSMIC (NCT06418204)
- Testing
- Non-interventional Study
- Where
- 491 sites in United States, Puerto Rico
- Volunteers
- 2,000 people
- Sponsor
- Wake Forest University Health Sciences
Hodgkin Lymphoma
Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma
Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ…
- Trial name
- NCT02624258
- Testing
- CD19 RNA redirected autologous T-cells (RNA CART19 cells)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pennsylvania
Non-Hodgkin's Lymphoma
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
The purpose of this trial is to investigate the efficacy (how well the drug works) of ofatumumab and lenalidomide in patients with lymphoma and to investigate if any possible unwanted side effects may occur.
- Trial name
- NCT01060384
- Testing
- Lenalidomide, ofatumumab
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
Non-Hodgkin's Lymphoma
A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients
The primary objective of the study is to evaluate the safety and tolerability of BAT4306F in patients with CD20-positive B-cell lymphoma
- Trial name
- NCT04152148
- Testing
- 500mg BAT4306F, 750mg BAT4306F, 900mg BAT4306F
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Bio-Thera Solutions
Gastrointestinal Neoplasms, Bronchial Carcinoma
Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training
The purpose of the study is to tests the hypothesis, that N-acetylcysteine (a thiol-antioxidant)improves the exercise training effect on cancer patients that experience weight loss (cachexia) as assessed by muscle mass and…
- Conditions
- Gastrointestinal Neoplasms, Bronchial Carcinoma, Hodgkin Disease, Non-Hodgkin Lymphoma
- Trial name
- NCT00196885
- Testing
- N-acetylcysteine
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- German Cancer Research Center
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL.
- Conditions
- Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma
- Trial name
- NCT02631044
- Testing
- JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule
- Where
- 14 sites in United States
- Volunteers
- 387 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Non-Hodgkin's Lymphoma, B-Cell ALL
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Patients have a type of lymph gland cancer called Non-Hodgkin Lymphoma (NHL), acute lymphocytic leukemia (ALL) or chronic lymphocytic leukemia (CLL) (these diseases will be referred to as "lymphoma" or "leukemia").
- Conditions
- Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL
- Trial name
- CARPASCIO (NCT02050347)
- Testing
- CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T Cells - dose escalation 1
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Baylor College of Medicine
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
The primary objective of this study is to assess the effect of treatment with bendamustine on cardiac repolarization as reflected by the rate-corrected QT interval by the Fridericia method (QTcF).
- Trial name
- NCT01073163
- Testing
- Bendamustine, Rituximab
- Where
- 43 sites in United States, Australia and 1 more
- Volunteers
- 54 people
- Sponsor
- Cephalon
Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory…
- Conditions
- Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL
- Trial name
- ACIT001/EXC002 (NCT03938987)
- Testing
- autologous CD19-directed chimeric antigen receptor (CAR) T-cells
- Where
- 6 sites in Canada
- Volunteers
- 63 people
- Sponsor
- University of Alberta
Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
- Conditions
- Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma
- Trial name
- NCT00006473
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma,Non-Hodgkin
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia
Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor to limit the dosage and the continuation of chemotherapy.
- Trial name
- NCT02996617
- Testing
- rhG-CSF regimen, Pegylated rhG-CSF regimen
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shandong Provincial Hospital
Follicular Lymphoma, Non-Hodgkin's Lymphoma
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
Background: The disease follicular lymphoma (FL) develops when the body makes abnormal B-cells. These cells usually build up in the lymph nodes, but can also affect other parts of the body.
- Conditions
- Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL
- Trial name
- NCT03789240
- Testing
- Rituximab, Copanlisib, Bone Marrow Aspiration/Biopsy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)